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Abstract
Recombinant human interleukin-2 (rhIL-2) was incorporated in liposomes for potential therapeutic applications using a
novel process. In this process, rhIL-2 caused the formation of large, unique multilamellar vesicles (MLVs) from small
unilamellar vesicles (SUVs) of dimyristoylphosphatidylcholine (DMPC). Vesicle coalescence occurred most rapidly at 19‡C,
between the pre- and main phase transition temperatures of DMPC, and showed a dependence upon pH (pH 6 5.5), ionic
strength (s 50 mM) and the initial size of the unilamellar vesicles (9 25 nm). Intermediates (partially coalesced vesicles)
within the forming multilamellar structures were identified by freeze-fracture electron microscopy and their presence was
corroborated by differential scanning calorimetry. Several distinct steps were identified in the coalescence process. In the
initial step, rhIL-2 rapidly bound to the DMPC SUVs. This was followed by a pH-dependent conformational change in the
protein, as evidenced by an increase in tryptophan fluorescence intensity. The SUVs then aggregated in large clusters that
eventually annealed to form closed MLVs. In this process over 90% of the rhIL-2 was bound to and incorporated within the
multilamellar structures. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Human interleukin-2 (IL-2) is a 15.5 kDa mono-
meric protein composed primarily of a bundle of
four K-helices [1,2]. Produced principally by T-lym-
phocytes of the Th1 helper cell subtype [3], IL-2
plays a role in the ampli¢cation of both humoral
and cell-mediated immunity [4^7]. It promotes the
proliferation of antigen-activated T-lymphocytes of
the helper and cytotoxic phenotypes, facilitates tu-
mor killing by activated macrophages, natural killer
cells and lymphokine-activated killer cells and in-
creases antibody production by B-cells. Recombinant
human interleukin-2 (rhIL-2) has shown promise as a
direct therapeutic agent [8^10] and is now approved
for two indications, renal cell carcinoma and malig-
nant melanoma. The systemic toxicity of rhIL-2,
however, has limited its clinical application [11].
rhIL-2 has been incorporated in liposomes for use
in cancer immunotherapy. The potential medical sig-
ni¢cance of such formulations is emphasized by the
many preclinical studies showing that liposomal
rhIL-2 is less toxic and more e⁄cacious than free
rhIL-2 [12^22]. This improved therapeutic index
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may be due to a liposome-dependent alteration of
the protein’s biodistribution and biopharmaceutics.
Incorporation of rhIL-2 into multilamellar liposomes
increased the serum half-life about 4-fold and caused
accumulation in the reticuloendothelial system
(RES), including lymphoid organs such as the spleen
and lymph nodes [23,24]. Other potentially advanta-
geous attributes of such formulations included spe-
ci¢c binding of the liposomes to immune cells ex-
pressing the IL-2 receptor [25] and the slow release
of free rhIL-2 under physiological conditions [25].
Incorporation of rhIL-2 into liposomes composed
of dimyristoylphosphatidylcholine (DMPC) has
been accomplished using standard methods such as
hydration from a thin ¢lm or multiple freeze^thaw
cycles [19,23]. The fact that the incorporation was
relatively high (greater than 50%) implied the exis-
tence of a direct interaction between rhIL-2 and lip-
id. This would be consistent with studies showing
that proteins and peptides which possess amphi-
pathic helices, like IL-2, interact with lipid bilayers
[26^29].
In studying the interaction between rhIL-2 and
DMPC, we noticed that rhIL-2 had the ability to
cause small unilamellar vesicles (SUVs) of DMPC
to form large, unique, multilamellar vesicles
(MLVs) with a mean diameter typically greater
than 2 Wm. Freeze-fracture electron microscopy and
vesicle leakage experiments de¢ned this process to be
coalescence and not fusion. The vesicles ¢rst aggre-
gated in large clusters of leaky SUVs that annealed
in time to form closed multilamellar bilayers. In this
manuscript, the kinetics and characteristics of this
MLV formation and its dependence on such factors
as temperature, pH, ionic strength and SUV size are
examined. This process, in which over 90% of the
rhIL-2 was bound to and incorporated within multi-
lamellar structures, represents a novel method of for-
mulating liposomes for therapeutic purposes.
2. Methods
2.1. Materials
rhIL-2 was provided by Ho¡mann-LaRoche (Nut-
ley, NJ) or manufactured at Biomira (Edmonton,
Alberta, Canada) using the Ho¡mann-LaRoche pro-
cess. The puri¢ed protein was stored in 50 mM so-
dium acetate, pH 3.5 containing 5 mg/ml mannitol.
In some experiments rhIL-2 was dialyzed against
1 mM phosphate bu¡er, pH 7. Dimyristoylphospha-
tidycholine (DMPC), dipalmitoylphosphatidylcholine
(DPPC), egg phosphatidylcholine (EPC), dimyris-
toylphosphatidylglycerol (DMPG), N-(7-nitro-2-1,3-
benzoxadiazol-4-yl)dimyristoylphosphatidylethanol-
amine (NBD-PE), N-(lissamine rhodamine B sul-
fonyl)dimyristoylphosphatidylethanolamine (Rhod-
PE) and cholesterol were manufactured by Avanti
Polar Lipids (Pelham, AL). N-Bromosuccinimide
was purchased from Sigma (St. Louis, MO). All oth-
er £uorescent probes and quenchers were obtained
from Molecular Probes (Junction City, OR). Alamar
blue was purchased from Biosource International
(Camarillo, CA). Microcon 100 ¢lters were from
Amicon (Beverly, MA).
2.2. SUV formation
MLVs were formed by direct hydration above the
main phase transition temperature of DMPC. Typi-
cally 0.8 ml of 1 mM phosphate bu¡er pH 7, 0.9%
saline at 37‡C was added to 200 mg of DMPC. For
mixtures of lipids, the lipids were ¢rst dissolved
in chloroform, following which a thin ¢lm was
formed in a round bottom £ask by evaporation
of the chloroform on a rotary evaporator. The thin
¢lm was subsequently hydrated as above. SUVs of
9 25 nm mean diameter were formed from MLVs
by size reduction employing either a bath sonicator
(Model G112SPIT, Laboratory Supplies, Hicksville,
NY) or a homogenizer such as a Gaulin Rannie
APV Model Mini-Lab type 7.30VH (Wilmington,
MA).
2.3. Large unilamellar vesicle (LUV) formation
LUVs were formed by extrusion of MLVs through
two stacked Nucleopore polycarbonate ¢lters (Pleas-
antville, CA) in an Extruder device (Lipex, Van-
couver, BC, Canada). The MLVs were appropriately
size reduced by sequential passage (5^10 passes each)
through stacked ¢lters of pore sizes 1.0, 0.4, 0.2,
0.08, 0.05, and 0.03 Wm.
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2.4. rhIL-2-induced coalescence process
DMPC SUVs or LUVs were incubated with rhIL-
2 at a lipid:rhIL-2 mass ratio of 250:1. Temperature,
incubation time, pH and ionic strength were varied
as described in the text. During pH experiments,
small amounts of 100 mM sodium citrate bu¡er
were used, i.e., the overall ionic strength was in-
creased approx. 11% (e.g. 50C56, 100C110,
150C165 mM). Optimal coalescence was observed
after 24 h incubation at 19‡C using limit size
DMPC SUVs (9 25 nm). The SUVs were prepared
in 150 mM NaCl containing 1 mM sodium phos-
phate bu¡er with the pH adjusted to pH 4 with so-
dium citrate, as described above.
2.5. Turbidity
Coalescence or aggregation was monitored by tur-
bidity at 660 nm on a Shimadzu UV-160U UV-Vis
spectrophotometer (Tokyo, Japan). Aliquots for time
points were diluted to 2 mg/ml DMPC prior to mea-
surement. Coalescence was con¢rmed by light mi-
croscopy.
2.6. Leakage assay
DMPC SUVs were formed in the presence of 10
mM 8-aminonaphthalene-1,3,6-trisulfonic acid
(ANTS) and 32 mM p-xylylene-bis-pyridinium bro-
mide (DPX). At these concentrations the DPX
quenches the ANTS. The SUVs were washed by di-
alysis and incubated in the presence of rhIL-2
(DMPC/IL-2 at 250:1, mass ratio) at di¡erent tem-
peratures. 100% leakage is determined by lysing the
SUVs with n-octyl glucoside. Measurements were
performed on a PTI QM-1 Luminescence Spectrom-
eter (Photon Technology International, South Bruns-
wick, NJ) with the excitation at 354 nm and the
emission at 370^600 nm.
2.7. Tryptophan £uorescence
Tryptophan (in rhIL-2) £uorescence experiments
were performed using a PTI QM-1 Luminescence
Spectrometer by exciting at 295 nm and recording
the emission between 310 and 400 nm. The temper-
ature was controlled ( þ 1‡C) by a Model RTE-100
water bath (Neslab Instruments, Portsmouth, NH).
Typically, 0.3^3.0 Wg of rhIL-2 in 3.0 ml aqueous
bu¡er was used. This sample could be completely
quenched for use as a background scatterer by add-
ing 5 Wl of a freshly prepared 10 mM N-bromosucci-
nimide solution. The ‘pure’ rhIL-2 tryptophan spec-
trum was obtained by subtracting the corresponding
background (‘quenched’ spectrum).
2.8. Lipid mixing
MLVs were prepared by the thin ¢lm method con-
taining DMPC, NBD-PE and rhodamine-PE at a
molar ratio of 98.8:0.4:0.8 [30]. These were sonicated
to form SUVs. The SUVs were mixed with blank
(non-£uorescent) DMPC SUVs at a 1:19 mass ratio
and incubated with and without rhIL-2. Excitation
was at 470 nm, with emission measured between 485
and 650 nm. The extent of energy transfer was moni-
tored by the ratio of peak intensities of NBD/rhod-
amine (520 nm and 586 nm, respectively) of the sam-
ple compared to that of a standard curve. The
standard curve was generated for complete mixing
at di¡erent ratios of blank to £uorescent SUVs that
were co-solubilized in chloroform/methanol (2:1).
The solvent was ¢rst evaporated with a stream of
nitrogen gas, then further dried under vacuum to a
thin ¢lm. The ¢lm was subsequently hydrated to
form MLVs.
2.9. % MLV formation
The % MLV formation was de¢ned as the total
lipid minus the lipid remaining in the supernatant
following centrifugation at 39 000Ug for 30 min at
4‡C, as determined by phosphate analysis [31].
2.10. IL-2 content, purity and incorporation
Total rhIL-2 was determined by a biological assay
employing an IL-2-dependent cell line, CTLL-2 [32],
and a standard IL-2 preparation calibrated in Inter-
national Units [33]. Diluted samples were added to
microtiter plates followed by the addition of CTLL-2
cells. Alamar Blue1, an oxidation^reduction indica-
tor that changes color in response to metabolites
released by the CTLL-2 cells, was used to monitor
cellular proliferation [34]. To determine the incorpo-
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ration of rhIL-2 in the liposomes, the samples were
diluted 1/100 in PBS containing 2 mg/ml HSA and
fractionated by centrifugation through Microcon0
100 ¢lters at 2700Ug for 15 min at 4‡C. The ¢ltrate
was assayed by the CTLL assay.
2.11. Particle sizing
Particle sizing for micron range liposomes was per-
formed on an AccuSizer 770 Optical Particle Sizer
(Particle Sizing Systems, Santa Barbara, CA.) This
works on the principle of single particle optical sens-
ing, where a sample is autodiluted such that one
particle at a time is counted. A NICOMP submicron
C370 instrument (Particle Sizing Systems) based on
dynamic light scattering was used for measuring par-
ticles below 1 Wm, in particular SUVs and LUVs.
2.12. Electron microscopy
Samples without cryoprotectant were placed be-
tween copper specimen carriers and rapidly plunged
into liquid propane. Fracturing and replicating was
performed at 3115‡C in a Balzers BAF 400T Freeze-
Etch unit (Liechtenstein). Cleaned replicas were
viewed on a Philips EM 300 transmission electron
microscope at a typical magni¢cation of 27 000
times.
2.13. Di¡erential scanning calorimetry (DSC)
DSC runs were performed on a CSC 4100 Multi-
cell Di¡erential Scanning Calorimeter (Calorimetry
Sciences Corp., Provo, UT). Normal saline solution
was used for baseline subtraction. Baseline subtrac-
tion, correction for the thermal instrument response
and conversion to heat capacity (WJ/‡C) as a function
of temperature were performed using software sup-
plied by CSC. The calorimetric data were imported
into Grams/32, v.5.0 (Galactic Industries Corp.,
Salem, NH) for baseline and o¡set correction,
smoothing and plotting. Data were not smoothed
or only minimally smoothed by using a Savitsky^
Golay smoothing routine. This method uses a con-
volution approach and performs a least squares ¢t to
a speci¢ed window. When data were smoothed a 3rd
order polynomial and a window of 5^11 data points
were typically employed. Scan rates were run at
20‡C/h in both heating and cooling directions.
3. Results
Saturated lecithins are known to undergo both a
pretransition and a main phase transition. For
DMPC these occur at about 15.5‡C and 24‡C, re-
spectively [35]. To determine the e¡ect of the lipid
phase on the interaction between rhIL-2 and SUVs,
the rhIL2-induced formation of multilamellar
vesicles was studied at various temperatures.
DMPC SUVs were mixed with rhIL-2 at a lipid:pro-
tein mass ratio of 250:1 at pH 4 in 150 mM NaCl
and incubated at 4, 19, 23.5 and 38‡C. An increase in
turbidity over time was observed at all temperatures
examined (Fig. 1). The e⁄ciency of MLV formation
Fig. 1. The e¡ect of temperature on the kinetics of DMPC
SUV coalescence as measured by turbidity. The DMPC/rhIL-2
mass ratio is 250:1. The temperatures were 4‡C (R), 19‡C (b),
23.5‡C (8), and 38‡C (F). Dashed lines with corresponding un-
¢lled symbols denote SUVs incubated in the absence of rhIL-2.
Table 1
Leakage experimentsa of DMPC SUVs (250 mg/ml) at 19‡C
Time (h) w/rhIL-2 (% leakage) Control (% leakage)
6 V12 6 2
12 V20 6 2
24 V28 6 2
aDMPC SUVs were preloaded with 10 mM ANTS and 32 mM
DPX.
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(see Section 2 for explanation) following 24 h incu-
bation in the presence of rhIL-2, was 74% at 4‡C,
94% at 19‡C and 34% at 23‡C. The optimal temper-
ature thus appeared to be 19‡C, a temperature be-
tween the pre- and main phase transitions of DMPC.
The dependence of MLV formation on rhIL-2 was
demonstrated by the minimal increase in turbidity
for control SUVs in the absence of rhIL-2 over the
same temperature range.
Creation of the multilamellar liposomes could
have occurred as a result of either vesicle fusion or
coalescence. Leakage experiments were performed to
distinguish between these two possibilities. During
vesicle fusion there is mixing of internal contents
with minimal leakage [36^38]. In contrast, during
vesicle coalescence leakage of internal contents oc-
curs. DMPC SUVs were formed in the presence of
10 mM ANTS and 32 mM DPX. At these concen-
trations the DPX quenches the ANTS. The SUVs
were washed by dialysis and incubated in the pres-
ence of rhIL-2 (DMPC:rhIL-2 at 250:1, by mass) at
19‡C. Leakage of the water-soluble ANTS and DPX
occurred during the process of forming multilayered
vesicles resulting in reduced quenching of the ANTS
Fig. 2. Freeze-fracture electron microscopy of the coalescence process which occurs upon incubation of DMPC SUVs with rhIL-2.
Time points were 0 h (A), 0.5 h (B,C), and 6 h (D). The reference bar equals 250 nm.
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signal as both components were diluted by the sur-
rounding bu¡er (Table 1). By 6 h about 12% of the
internal contents had leaked compared to less than
2% for control SUVs incubated without rhIL-2. A
28% leakage was observed at 24 h. This observation,
coupled with the freeze-fracture EM micrographs
(Fig. 2) which showed large aggregates breaking up
and annealing to form large MLVs, indicates that the
process was primarily coalescence and not fusion.
Freeze-fracture electron microscopy was employed
to follow the kinetics of the turbidity increase and to
characterize the product. At various time points ali-
quots of the SUV/rhIL-2 sample incubated at 19‡C
were rapidly frozen between thin copper specimen
carriers in preparation for freeze-fracture. The initial
SUVs were 9 25 nm (Fig. 2A). At 30 min most of the
replica revealed intact SUVs, but some regions re-
vealed large aggregates or partially coalesced SUVs
(Fig. 2B). Also seen at 30 min (Fig. 2C) were SUVs
clearly £attening and coalescing to form bilayer
sheets, as indicated by the characteristic PL0 (ripple)
phase typically observed for DMPC vesicles at this
temperature. By 6 h (Fig. 2D) large multilayered
vesicles were formed which contained bulges in the
surface texture of the individual layers. Some SUVs
were still present, indicating incomplete coalescence.
By 24 h large multilayered vesicles were present with
few uncoalesced SUVs (data not shown). The bulges
were noted throughout the MLV structure, indicat-
ing that rhIL-2 was entrapped within the interlamel-
lar spacings. The ¢nal liposomes had a mean diam-
eter of 2.37 Wm, as measured on an Accusizer 770
particle sizing system. The resultant multilayered
vesicles were analyzed for the presence of rhIL-2,
using the CTLL-2 bioassay. Activity was 2.17U106
IU/ml, with an 89% recovery and greater than 95%
incorporation of rhIL-2 into vesicles.
The kinetics of the transition from SUVs to MLVs
was also examined using DSC. As previously re-
ported by Mabrey and Sturtevant [39], the starting
DMPC SUVs exhibited a typical broad main phase
transition at about 20‡C followed by a small sharper
transition at 25.7‡C, the latter due to some multi-
layer contamination (Fig. 3, curve a). Upon incuba-
tion with rhIL-2, the broad transition peak appeared
to break up into two separate peaks (Fig. 3, curve b).
These in time vanished as the vesicles continued to
coalesce (Fig. 3, curves c^e). The DSC tracing of the
¢nal product (Fig. 3, curve e) was identical to that of
MLVs without rhIL-2 (Fig. 3, curve f), but with a
15% drop in the main phase transition enthalpy as
well as a slight downward shift in the pretransition
temperature.
The interactions of proteins or peptides with mem-
branes are altered by pH and ionic strength, espe-
cially when they contain amphipathic helices [40,41]
like the D K-helix of rhIL-2 [42]. To study the e¡ect
of pH on the coalescence process, turbidity was
monitored at speci¢c pH values at 19‡C using cit-
rate^phosphate bu¡er to adjust the pH of the reac-
tion mixture. To minimize the e¡ect on overall ionic
strength (the reaction mixture contained 150 mM
NaCl), the ¢nal citrate bu¡er concentrations were
kept at 1^5 mM. As shown in Fig. 4A, coalescence
of DMPC SUVs did not occur until the pH was
Fig. 3. DSC pro¢le of rhIL-2-induced SUV coalescence. Scans
were taken following an incubation at 19‡C of DMPC SUVs
and rhIL-2 at 200 mg/ml and 0.8 mg/ml respectively. Incuba-
tion times at 19‡C were 0 min (a), 30 min (b), 2 h (c), 6 h (d),
and 24 h (e). Control DMPC MLVs in the absence of rhIL-2
are also shown (f). Note that the actual measurements are not
precisely at the time points stated, since approx. 20 min were
required to lower the DSC cell temperature before beginning
the heating scan at 20‡C/h.
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below 6. Coalescence was abundant at and below pH
5.5, with an increase in both the rate and extent as
the pH was lowered to 3.6. No signi¢cant coales-
cence was observed over this pH range in the absence
of rhIL-2.
The e¡ect of pH on rhIL-2-dependent coalescence
of DMPC SUVs was further investigated by moni-
toring the £uorescence of the single tryptophan at
position 121 in the native protein [43]. At pH 5.9 a
slight increase in tryptophan £uorescence intensity
was observed (Fig. 4B). As the pH of the reaction
mixture was lowered, a time-dependent increase in
tryptophan £uorescence intensity was observed. At
low pH values the increase in £uorescence was rapid
and leveled o¡ by 6 h. Little further increase was
Fig. 4. The e¡ect of pH on the kinetics of rhIL-2-induced
DMPC SUV coalescence. The time course was measured at
19‡C as a function of (A) turbidity, (B) tryptophan £uores-
cence, and (C) % incorporation of rhIL-2. The pH values em-
ployed were 3.6 (a), 4.0 (b), 4.5 (S), 5.0 (P), 5.5 (F), 5.9 (E),
6.6 (R), 7.4 (O), and 8.2 (8). The time course for rhIL-2 in
the absence of DMPC SUVs is shown at pH 4 (solid line), pH
5 (dashed) and pH 6 (dotted).
Fig. 5. The e¡ect of ionic strength on the kinetics of rhIL-2-in-
duced DMPC SUV coalescence. The time course was measured
at 19‡C as a function of (A) turbidity and (B) tryptophan £uo-
rescence. The concentrations of NaCl employed were 0 mM
(b), 10 mM (S), 50 mM (F), and 150 mM (8).
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observed up to 24 h. The increase of tryptophan
£uorescence in liposomal rhIL-2 over free rhIL-2 at
the appropriate pH values was as much as 10-fold
(Fig. 4B) and exhibited a 3^5 nm red shift in the
tryptophan £uorescence maximum (data not shown).
The kinetics of the actual binding of rhIL-2 to
SUVs at di¡erent pH values was monitored by re-
moving an aliquot of the reaction mixture and mea-
suring the rhIL-2 incorporation by the CTLL-2 bio-
assay. The binding appeared to be almost
instantaneous, with greater than 90% of the rhIL-2
bound within 15 min for samples at pH 4.0, 5.0, 5.5
and 5.9 (Fig. 4C).
The e¡ect of ionic strength on the rhIL-2-depen-
dent coalescence process was examined using DMPC
SUVs made in speci¢ed saline concentrations be-
tween 0 mM and 150 mM, all at pH 4 and 19‡C
(Fig. 5). Turbidity measurements (Fig. 5A) revealed
an absence of coalescence at 0 mM NaCl and a
steady increase as the salt concentration was raised
to 150 mM. Tryptophan £uorescence measurements
revealed a rapid initial increase in £uorescence inten-
sity of about 5-fold at 0 and 10 mM NaCl and an
almost 10-fold increase at 50 and 150 mM NaCl
(Fig. 5B). Binding of rhIL-2, as determined by the
CTLL-2 bioassay, was independent of saline concen-
tration. Greater than 90% of the rhIL-2 was bound
to the SUVs at all NaCl concentrations within the
¢rst 15 min of incubation (data not shown).
The data shown above demonstrated that the
rhIL-2-dependent coalescence process was optimal
at 19‡C, at pH 4 and in 150 mM NaCl. During the
formation of MLVs, lipid mixing must occur as the
SUV bilayers merge to form the planar bilayers
found in MLVs. Lipid mixing experiments (see Sec-
tion 2 for details) were performed at 19‡C in 150 mM
NaCl and at pH 4 and 6. As expected from other
experiments (Fig. 4), no lipid mixing was observed at
pH 6 following 24 h (data not shown), while signi¢-
cant lipid mixing was found at pH 4. To examine the
kinetics of the various stages in the coalescence pro-
cess, Fig. 6 combines the pH 4 lipid mixing data with
the early time point measurements of turbidity, tryp-
tophan £uorescence and rhIL-2 incorporation (Fig.
4, pH 4 and 150 mM NaCl). The data are expressed
as a percent of maximum values (6 h incubation time
point). It is apparent that the rhIL-2 ¢rst bound to
the SUVs (CTLL-2 results), followed by a structural
change in the protein, as evidenced by the increase in
tryptophan £uorescence. This in turn was followed
by an increase in SUV aggregation, as indicated by a
rise in turbidity, and then coalescence, as indicated
by the lipid mixing data.
SUVs are known to be inherently more susceptible
to fusogenic reagents than LUVs [44]. To test the size
dependence of the coalescence process, DMPC LUVs
of various sizes were made by extrusion through a
series of polycarbonate ¢lters. These LUVs were then
incubated at 19‡C with rhIL-2 at a lipid:protein
mass ratio of 250:1 and a DMPC concentration of
200 mg/ml. As shown in Table 2, LUVs that were
initially 56 nm in diameter yielded a mixture of coa-
lescence products and unaltered vesicles following an
Fig. 6. The kinetics of the interaction of rhIL-2 with DMPC
SUVs at pH 4, 150 mM NaCl. The % total refers to the % of
the value after a 6 h incubation, the plateau of each of the ef-
fects monitored. The rhIL-2 binding as determined by the
CTLL-2 bioassay (b), the increase in tryptophan £uorescence
(S), and the turbidity (8) are from Fig. 4. Lipid mixing (F),
an indication of coalescence, was determined by mixing DMPC
SUVs with DMPC/NBD-PE/Rhod-PE (98.8:0.4:0.8, molar ra-
tios) SUVs at a 19:1 ratio and incubating at 19‡C with rhIL-2
at a lipid:protein mass ratio of 250:1.
Table 2
Coalescence of LUVs
Filter size (nm) Initial (nm) 1 day (nm) 11 days (nm)
30 56 57 (29%) 2482
1023 (71%)
50 62 60 85
80 72 70 81
100 83 86 88
200 124 127 132
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overnight incubation with rhIL-2. These LUVs con-
tinued to coalesce over a period of 11 days, yielding
MLVs of approx. 2.5 Wm in diameter. LUVs initially
above 60 nm did not coalesce to any signi¢cant de-
gree during the 11 day incubation period (Table 2),
nor did any of the LUVs coalesce in the absence of
rhIL-2. A more detailed examination of the rhIL-2
interaction with LUVs was performed on the 124 nm
vesicles. The £uorescence of tryptophan did not
change upon incubation overnight at 19‡C at pH 6
(Fig. 7A). At pH 4, a 2-fold increase was observed by
5 h and a 5-fold increase at 24 h. Binding data based
on the CTLL-2 bioassay again showed a rapid asso-
ciation of rhIL-2 at both pH values, although a max-
imum of only 80% incorporation was attained (Fig.
7B). An electron micrograph of the 124 nm vesicles
following a 24 h incubation at 19‡C and pH 4 re-
vealed many unaltered LUVs, consistent with the
particle sizing data (Table 2). A few multilayered
vesicles were present with incomplete or partially co-
alesced LUVs within the structures (Fig. 8).
4. Discussion
In this manuscript we describe a rhIL-2-dependent
formation of MLVs from SUVs resulting in s 90%
incorporation of rhIL-2 into the multilamellar struc-
tures. Optimal conditions for the MLV formation
were achieved when rhIL-2 was added to limit size
(925 nm) DMPC SUVs at 19‡C (Fig. 1) in 150 mM
NaCl at pH 4 (Figs. 4 and 5). The mechanism of
MLV formation was determined to be coalescence,
not fusion, based on leakage experiments (Table 1)
and freeze-fracture EM (Fig. 2). The process was
initiated by rapid binding of rhIL-2 to DMPC
SUVs, which was then followed by a pH- and ionic
strength-dependent conformational change in the
protein (Figs. 4 and 6). Under optimal conditions,
the latter step, as measured by the change in trypto-
phan £uorescence intensity, was complete by 1 h
(Fig. 6). This appeared to promote SUV aggregation
into large clusters. The large clusters formed inter-
mediate structures (Figs. 2A^D and 3) which then
annealed in time, resulting in the mixing of lipid
Fig. 7. The e¡ect of pH on the kinetics of rhIL-2-induced
DMPC LUV coalescence. The time course was measured as a
function of (A) tryptophan £uorescence and (B) % incorpora-
tion of rhIL-2. The pH values employed were 4.0 (b) and 6.0
(S).
Fig. 8. Freeze-fracture electron microscopy of DMPC LUVs in-
cubated with rhIL-2 for 24 h at 19‡C. The initial LUVs were
124 nm. The reference bar equals 250 nm.
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contents (Fig. 6) and formation of closed MLVs.
These interpretations and a hypothetical mode of
rhIL-2/bilayer interaction are discussed below.
The temperature at which the rhIL-2 interacted
most favorably with DMPC SUVs was 19‡C, based
on the turbidity increase and coalescence e⁄ciency.
This is between the pretransition and main transition
temperatures of DMPC MLVs, but within the main
transition temperature of DMPC SUVs. The asym-
metric distribution of phospholipid molecules in
SUVs leads to the broader transition at a lower tem-
perature and enthalpy than that of MLVs [39]. The
enhanced ability of the rhIL-2 to interact with SUVs
and induce coalescence at 19‡C could be due to the
looser, more distorted packing in the SUVs at this
temperature. The diminished coalescence observed
below the pretransition temperature (Fig. 1) could
also be due in part to a competing spontaneous
vesicle fusion event. Spontaneous fusion of SUVs
composed of saturated lecithins to form vesicles of
about 70 nm size is known to occur below the pre-
transition temperature of the phospholipid [45].
LUVs of this size range were found to resist rhIL-
2-dependent coalescence to MLVs (Table 2).
Following the rapid association of rhIL-2 with
DMPC SUVs, a conformational change in the pro-
tein was detected by an increase in tryptophan £uo-
rescence intensity. rhIL-2 contains a single trypto-
phan located in the amphipathic D-helix. Polarized
£uorescence decay of the tryptophan indicates that
intramolecular quenching occurs in the native mole-
cule [27]. A conformational change a¡ecting the local
environment of the tryptophan or its distance from a
quenching moiety would result in an increase in £uo-
rescence intensity. Just such an increase was observed
following binding of rhIL-2 to SUV lipid bilayers
(Fig. 4). The magnitude and kinetics of the change
in tryptophan £uorescence intensity were dependent
on both pH and ionic strength, being optimal at pH
4 and 150 mM NaCl (Figs. 4 and 5). A small red
shift of 3^5 nm in the tryptophan emission wave-
length maximum was also noted (data not shown).
Such a shift would be consistent with hydrogen
bonding or a dipole^dipole interaction involving
the tryptophan imino group (vide infra). Changes
in the tryptophan £uorescence intensity and emission
maximum were not observed for free rhIL-2 over a
wide pH range (Fig. 4B), demonstrating the depen-
dence upon adsorption to the DMPC SUV bilayer.
The conformational change involving Trp 121 of
rhIL-2 appeared to precede the increased turbidity
indicative of SUV aggregation and the subsequent
lipid mixing and coalescence which resulted in
MLV formation (Fig. 6).
Formation of MLVs proceeded through intermedi-
ate structures and was dependent upon vesicle coa-
lescence. Aggregation of SUVs following rhIL-2
binding was detected by DSC and freeze-fracture
EM. At both 30 min and 2 h a low enthalpy shoulder
appeared prior to the main transition temperature
observed for DMPC MLVs (Fig. 3, curves a, b).
Additionally, a low enthalpy peak appeared above
the pretransition temperature (Fig. 3, curve b).
Both of these peaks appeared as the broad SUV
main transition peak disappeared. The nature of
these peaks could represent partially coalesced
SUVs, as seen by freeze-fracture EM in Fig. 2B,C.
Binding of rhIL-2 to DMPC SUVs (Fig. 2A) results
in an aggregation of these vesicles (Fig. 2B). The
large clusters coalesce through intermediate struc-
tures (Fig. 2C) to ¢nally form the rhIL-2-rich MLV
structures exhibiting their signature bulges and ripple
phase (Fig. 2D).
Compared to control DMPC MLVs (without
rhIL-2), the endotherms at both 6 and 24 h exhibited
a 15% lower enthalpy for both the DMPC bilayer
pre- and main phase transitions and did not show
transition peak broadening. This is consistent with
a surface or interfacial bound rhIL-2 removing a
fraction of the lipid molecules from participating in
the phase transitions [46].
In addition to its e¡ect on the rhIL-2 conforma-
tional change (Fig. 5B), higher medium ionic
strength likely in£uences the speed and extent of
SUV coalescence (Fig. 5A) by reducing the Debye
length of the Gouy^Chapman double layer sur-
rounding the SUVs [47] and allowing a closer ap-
proach of DMPC bilayers. Coalescence would be
enhanced by the proximity of opposing bilayers in
conjunction with a local accumulation of a fusogenic
molecule (rhIL-2) and bilayer defects (optimal ap-
prox. 19‡C for DMPC). The increase in ionic
strength may also participate in relieving the £uores-
cence quenching of tryptophan within SUV-bound
rhIL-2 by neutralizing electrostatic interactions.
Such neutralization could promote or stabilize the
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conformational change(s) in rhIL-2, which may in
turn promote the formation of bilayer defects.
Based on the above considerations, we propose a
hypothetical mode of rhIL-2-induced SUV coales-
cence involving an interaction of tryptophan residue
#121 of the amphipathic D K-helix of rhIL-2 with
the bilayer interface of DMPC SUVs, leading to co-
alescence. In such an interaction, higher medium
ionic strength would promote the proximity of op-
posing bilayers, while conformational change(s) in
bound rhIL-2 would destabilize the DMPC SUV bi-
layers. The observed conformational change in rhIL-
2 following binding to DMPC SUVs a¡ects the tryp-
tophan residue #121 environment, as demonstrated
by the change in tryptophan £uorescence intensity.
That this change in £uorescence could signal a direct
role for tryptophan residue #121 at the bilayer inter-
face is supported by studies of Yau et al. [48], who
used 1H magic angle spinning (MAS), two-dimen-
sional nuclear Overhauser e¡ect spectroscopy (2D-
NOESY), 1H MAS NMR and solid state 2H NMR
to study the interactions of tryptophan analogues
with phosphatidylcholine membranes. They reported
on the preference of tryptophan residues for mem-
brane interfaces, speci¢cally, in the vicinity of the
glycerol group. This interaction caused modest
changes in the acyl chain organization, with minimal
penetration of tryptophan into the bilayer proper.
These workers concluded that tryptophan’s £at rigid
shape limited its access to the hydrocarbon core.
Moreover, its Z electronic structure and associated
quadrupolar moment (aromaticity) favored this elec-
trostatically complex interface environment. The 3^5
nm red shift in the tryptophan £uorescence maxi-
mum noted above during the rhIL-2-dependent coa-
lescence of SUVs would be consistent with the sug-
gestion of Yau et al. [48] of an imino group hydrogen
bonding or dipole^dipole interaction in this interfa-
cial region. In addition, the DSC data (Fig. 3) and
the freeze-fracture EM data (Fig. 2) exhibited an
unperturbed PL0 phase, which implies a minimal pen-
etration of rhIL-2 into the DMPC bilayer’s hydro-
carbon core.
The lipid-bound rhIL-2 did not induce coalescence
in the case of LUVs of s 60 nm diameter (Table 2).
Moreover, the increase in tryptophan £uorescence
intensity was slower in the presence of LUVs than
with SUVs and was only about 2-fold over the ¢rst
6 h (Fig. 7A). These observations are similar to those
made with large multilamellar vesicles [27]. Since
MLVs and LUVs possess relatively planar bilayer
surfaces, a conformational change in rhIL-2 involv-
ing a partial penetration of tryptophan into the hy-
drocarbon core of the bilayer would be restricted.
This could explain the longer time and only 2-fold
increase in tryptophan £uorescence intensity. In ad-
dition, the already £at planar bilayers are not under
the same strain as those of DMPC SUVs. Thus they
would be less likely to fragment, a step required for
the formation of multilamellar vesicles. The lack of
LUV coalescence is consistent with previous studies
demonstrating that LUVs are more stable than
SUVs. SUVs, but not LUVs, exhibited lipid mixing
at pH 5 in the presence of the peptide GALA [40]
and LUVs were found to marginally fuse while SUVs
displayed extensive fusion in the presence of PEG
[44].
The coalescence phenomenon described in this pa-
per is not limited to DMPC, as SUVs of other lipids
including DPPC, DMPC/cholesterol, DMPC/DMPG
and EPC exhibited varying degrees of coalescence in
the presence of rhIL-2 (unpublished observations).
Additionally, a similar ability to cause SUVs to coa-
lesce has been noted for other cytokines of the hem-
atopoietic family which possess K-helical bundle
structures [49], such as granulocyte^macrophage col-
ony stimulating factor (GM-CSF) and recombinant
human Interleukin-4 (unpublished observations).
Hence, the process o¡ers a novel, scalable method
for the manufacture of many di¡erent liposomal for-
mulations composed of various cytokines of the hem-
atopoietic family, forming MLVs with cytokine not
just on the surface, but within the interlamellar spac-
ings. This would allow for both a depot e¡ect and
altered pharmacological properties and biodistribu-
tion. Studies are underway to extend these observa-
tions to other cytokine families [49].
References
[1] J.F. Bazan, Science 257 (1992) 410^412.
[2] D.B. McKay, Science 257 (1992) 412^413.
[3] K.A. Smith, Science 240 (1988) 1169^1176.
[4] M.K. Jenkins, D.M. Pardoll, J. Mizuguchi, T.M. Chused,
R.H. Schwartz, Proc. Natl. Acad. Sci. USA 34 (1987)
5409.
BBAMEM 78143 6-8-01
L.T. Boni et al. / Biochimica et Biophysica Acta 1514 (2001) 127^138 137
[5] M. Malkovsky, B. Loveland, M. North, G.L. Asherson, L.
Gao, P. Ward, Nature 325 (1987) 262^265.
[6] E.A. Grimm, R.J. Robb, J.A. Roth, L.M. Neckers, L.B.
Lachman, D.J. Wilson, S.A. Rosenberg, J. Exp. Med. 158
(1983) 1356^1361.
[7] J.B. Splawski, L.M. McAnally, P.E. Lipsky, J. Immunol. 144
(1990) 562^569.
[8] S.A. Rosenberg, J.J. Mule, P.J. Spiess, C.M. Reichert, S.L.
Schwarz, J. Exp. Med. 161 (1985) 1169^1188.
[9] S.A. Rosenberg, M.T. Lotze, L.M. Muul, A.E. Chang, F.P.
Avis, S. Leitman, W.M. Linehan, C.N. Robertson, R.E. Lee,
J.T. Rubin, C.A. Seipp, C.G. Simpson, D.E. White, New
Engl. J. Med. 316 (1987) 889^897.
[10] R. Whittington, D. Faulds, Drugs 46 (1993) 446^514.
[11] J.P. Siegal, R.K. Puri, J. Clin. Oncol. 9 (1991) 694^704.
[12] P.M. Anderson, E. Katsanis, A.S. Leonard, D. Schow, C.M.
Loe¥er, M.B. Goldstein, A.C. Ochoa, Cancer Res. 50 (1990)
1853^1856.
[13] E. Kedar, E. Braun, Y. Rutkowski, N. Emanuel, Y. Baren-
holz, J. Immunother. 16 (1994) 115^124.
[14] A. Adler, J. Schachter, Y. Barenholz, L.K. Bar, T. Klein, R.
Korytnaya, A. Sulkes, R. Michowiz, Y. Cohen, I. Kedar,
Cancer Biother. 10 (1995) 293^306.
[15] N. Gershman, D. Johnston, J.C. Bystryn, Vaccine Res. 3
(1994) 83^92.
[16] C.M. Loe¥er, J.L. Platt, P.M. Anderson, E. Katsanis, J.B.
Ochoa, W.J. Urba, D.L. Longo, A.S. Leonard, A.C. Ochoa,
Cancer Res. 51 (1991) 2127^2132.
[17] S.F. Sencer, M.L. Rich, E. Katsanis, A.C. Ochoa, P.M. An-
derson, Eur. Cytokine Netw. 2 (1991) 311^318.
[18] P.M. Anderson, D. Hasz, L. Dickrell, S. Sencer, Drug Dev.
Res. 27 (1992) 15^31.
[19] J.J. Bergers, W. Den Otter, H.F.J. Dullens, C.T.M. Kerk-
vliet, D.J.A. Crommelin, Pharm. Res. 10 (1993) 1715^1721.
[20] F.J. Koppenhagen, Z. Ku«pcu«, G. Wallner, D.J.A. Cromme-
lin, E. Wagner, G. Storm, R. Kircheis, Clin. Cancer Res. 4
(1998) 1881^1886.
[21] O.C. Krup, I. Kroll, G. Bo«se, F.W. Falkenberg, J. Immun-
other. 22 (1999) 525^538.
[22] F.J. Koppenhagen, L.T.M. Balemans, P.A. Steerenberg,
T.M. Jagmont, W. Den Otter, G. Storm, J. Liposome Res.
9 (1999) 313^329.
[23] P.M. Anderson, E. Katsanis, S.F. Sencer, D. Hasz, A.C.
Ochoa, B. Bostrom, J. Immunother. 12 (1992) 19^31.
[24] M.E. Neville, K.W. Richau, L.T. Boni, L.E. P£ug, R.J.
Robb, M.P. Popescu, Cytokine 12 (2000) 1702^1711.
[25] M.E. Neville, L.T. Boni, L.E. P£ug, M.C. Popescu, R.R.
Robb, Cytokine 12 (2000) 1691^1701.
[26] W.C. Wimley, S.H. White, Nat. Struct. Biol. 3 (1996) 842^
848.
[27] F.J. Koppenhagen, A.J.W.G. Visser, J.N. Herron, G. Storm,
J.A. Crommelin, J. Pharm. Sci. 87 (1998) 707^714.
[28] G. Beschiaschvili, J. Seelig, Biochemistry 29 (1990) 52^58.
[29] R.M. Epand, L.T. Boni, S.W. Hui, Biochim. Biophys. Acta
692 (1982) 330^338.
[30] D.K. Struck, D. Hoekstra, R.E. Pagano, Am. Chem. Soc. 20
(1981) 4093^4099.
[31] B.N. Ames, Methods Enzymol. 8 (1966) 115^117.
[32] S. Gillis, M.M. Ferm, W. Ou, K.A. Smith, J. Immunol. 120
(1978) 2027^2032.
[33] A.J.H. Gearing, R. Thorpe, J. Immunol. Methods 114 (1988)
3^9.
[34] S.A. Ahmen, R.M. Gogal Jr., J.E. Walsh, J. Immunol.
Methods 170 (1994) 211^224.
[35] J.P. Dufour, R. Nunnally, L. Buhle Jr., T.Y. Tsong, Bio-
chemistry 20 (1981) 5576^5586.
[36] D. Gingell, L. Ginsberg, in: G. Poste, G.L. Nicolson (Eds.),
Membrane Fusion, Elsevier/North-Holland Biomedical
Press, New York, 1978, pp. 791^833.
[37] F. Szoka, in: A.E. Sowers (Ed.), Cell Fusion, Plenum Press,
New York, 1987, pp. 209^240.
[38] S. Nir, J. Wilschut, J. Bentz, Biochim. Biophys. Acta 688
(1982) 275^278.
[39] S. Mabrey, J.M. Sturtevant, in: E.D. Korn (Ed.), Methods
in Membrane Biology, Plenum Press, New York, 1978, pp.
237^274.
[40] R.A. Parente, S. Nir, F.C. Szoka Jr., J. Biol. Chem. 263
(1988) 4724^4730.
[41] J.F. Hunt, P. Rath, K.J. Rothschild, D.M. Engelman, Bio-
chemistry 36 (1997) 15177^15192.
[42] R.M. Epand, R.F. Epand, R.C. Orlowski, R.J. Schlueter,
L.T. Boni, S.W. Hui, Biochemistry 22 (1983) 5074^5084.
[43] T. Taniguchi, H. Matsui, T. Fujita, C. Takaoka, N. Kashi-
ma, R. Yoshimoto, J. Hamuro, Nature 302 (1983) 305^310.
[44] L.T. Boni, J.S. Hah, S.W. Hui, P. Mukherjee, J.T. Ho, C.Y.
Jung, Biochim. Biophys. Acta 775 (1984) 409^418.
[45] C.F. Schmidt, D. Lichtenberg, T.E. Thompson, Biochemis-
try 20 (1981) 4792^4797.
[46] T.D. Bradrick, E. Friere, S. Georghiou, Biochim. Biophys.
Acta 982 (1989) 94^102.
[47] N.O. Petersen, S.I. Chan, Biochim. Biophys. Acta 509 (1978)
111^128.
[48] W.M. Yau, W.C. Wimley, K. Gawrisch, S.H. White, Bio-
chemistry 20 (1998) 14713^14718.
[49] N.A. Nicola (Ed.), Guidebook to Cytokines and Their Re-
ceptors, Oxford University Press, Oxford, 1994.
BBAMEM 78143 6-8-01
L.T. Boni et al. / Biochimica et Biophysica Acta 1514 (2001) 127^138138
